Filing Flows › Bioadaptives (BDPT) › Q2 2026
Bioadaptives (BDPT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 19, 2026
Bioadaptives (BDPT) reported revenue of $5K for the second quarter 2026 (Q2 2026), +55% from a year earlier and -10% from the quarter before.
Bioadaptives, Q2 2026: revenue $5K (+55% year over year), net earnings $150K, operating cash flow −$44K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5K | -10% | +55% |
| Operating profit | −$197K | — | — |
| Net earnings | $150K | — | — |
| Operating cash flow | −$44K | — | — |
What changed
Revenue was $5K in Q2 2026, up 55% year over year and down 10% from the previous quarter.
Gross margin was 85.0%, up 52.0 points from Q2 2025. Operating costs exceeded revenue by $197K, an operating margin of -3953.0%. Operating expenses fell 28% while revenue rose 55%. Net earnings were $150K. The effective tax rate was 0.0%. Non-operating items added $347K, 231% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$44K. Non-cash charges added back $2K of depreciation. Working capital and other items used $196K.
Questions
What was Bioadaptives' revenue in the second quarter 2026?
Bioadaptives (BDPT) reported revenue of $5K for the second quarter 2026 (Q2 2026), +55% from a year earlier and -10% from the quarter before.
Source: Bioadaptives 10-Q on SEC EDGAR.